Nouscom Secures €75.8 Million Series C Investment Boost for Advancing Cancer Vaccine Development

Angelini Ventures, the corporate venture firm of Angelini Industries, has announced its participation in an extended Series C financing round for Nouscom, a pioneering immuno-oncology company.

The investment, totaling €7 million, contributes to Nouscom's overall funding of €75.8 million ($82 million). This oversubscribed financing round backed by a syndicate of top-tier international healthcare investors, aims to fuel Nouscom's clinical advancements in cancer vaccines. The investment signifies Angelini Ventures' continued commitment to fostering innovation in the healthcare sector.

Nouscom exemplifies the caliber of companies we are eager to support – biotechs at the forefront of innovation with a potential to revolutionize patient care. Our investment reflects confidence in Nouscom's distinguished team, cutting-edge technology, and promising clinical pipeline.

Paolo Di Giorgio, Role: Chief Executive Officer of Angelini Ventures

Nouscom's Series C financing round, initially unveiled in November 2023, has drawn significant interest from a syndicate of top-tier international healthcare investors. Alongside Angelini Ventures, new seasoned investors such as Andera Partners, Bpifrance, M Ventures, and Revelation Partners, among others, have joined forces with existing backers including 5AM Ventures, EQT Life Sciences, and Versant Ventures.

As stakeholders of Angelini Ventures, we prioritize investments that not only deliver financial returns but also contribute to meaningful advancements in healthcare. Our partnership with Nouscom aligns perfectly with our long-term commitment to transforming the global healthcare landscape.

Prof. Sergio Marullo di Condojanni, Role: CEO of Angelini Industries

The influx of capital will empower Nouscom to further advance its clinical pipeline, particularly focusing on the development of neoantigen cancer vaccines. Notable milestones include the ongoing Phase 2 trial for NOUS-209, an off-the-shelf vaccine targeting Mismatch Repair/Microsatellite Instable (dMMR/MSI) Metastatic Colorectal Cancer (mCRC). Additionally, the Company aims to complete Phase 1b studies for NOUS-209 monotherapy in Lynch Syndrome (LS) carriers, exploring avenues to intercept, prevent, or delay cancer onset in high-risk individuals. Furthermore, the financing will facilitate the progression of NOUS-PEV, a personalized cancer immunotherapy, in combination with checkpoint inhibitors for advanced melanoma, with plans to initiate Phase 2 trials in high unmet medical need indications.

We are thrilled to extend our Series C financing round and welcome Angelini Ventures aboard. Their partnership underscores our dedication to innovation and accelerates our pursuit of groundbreaking cancer treatments.

Marina Udier, Role: Chief Executive Officer and Board Director, Nouscom AG

With Angelini Ventures' investment, Nouscom is poised to strengthen its position as a frontrunner in immuno-oncology, driving forward its mission to redefine standards of cancer care through innovative vaccine therapies.